K T Rama Rao unveils BE's 300 Crore plant at Hyderabad

▴ K T Rama Rao unveils BEs 300 Crore plant at Hyderabad
Hyderabad based pharmaceutical co. Biological E Ltd.recently launched its new plant of Rs.300 crores at Genome Valley. This initiative will enhance the production and manufacture of new vaccines.

Pharmaceutical company Biological E. Limited on 17.02.2020 launched its new plant, built with an investment of Rs. 300 crore at Genome Valley here.Telangana's Industry Minister K.T. Rama Rao inaugurated the facility, which will generate employment for about 1,000 people.

Mahima Datla, Managing Director, Biological E. Limited, this new facility will help their existing vaccines plant enhance the production and manufacture new products, which are in the pipeline.The plant has come up on 29 acres in the Special Economic Zone at Genome Valley in Kolthur village on the outskirts of Hyderabad.

Kiran Mazumdar Shaw, Chairperson and Managing Director, Biocon, Professor Baron Peter Piot, Director, London School of Hygiene and Tropical Medicine were also present.

Rao said the government was committed to make Telangana number one state in terms of industrial growth and employment generation with a special focus on life sciences.Rama Rao also unveiled BE's Typhoid Conjugate Vaccine. Recently, BE received the authorisation from the health regulatory authorities of India to license and market TCV.

TCV is an injectable single-dose vaccine to be administered to children of the age of above 6 months as well as adults. The clinical studies conducted in India demonstrated that the safety and immunogenicity profiles of this vaccine are comparable to the other licensed and WHO Pre-qualified Typhoid conjugate vaccine, Biological E. said.

This vaccine was developed in partnership with the GSK Vaccines Institute for Global Health, based in Siena (Italy), which first developed the asset and transferred it to BE in 2013. Subsequent developmental work on the vaccine was done by BE, including manufacturing process optimization and scale up, pre-clinical studies and full clinical trials in India.

This vaccine will be manufactured in BE's GMP manufacturing facilities in Hyderabad, India and could be commercially available within 3 months, it added.

Story Source : IANS

Tags : #Ktramarao #Hyderabadbasedbiologicaleltd #Typhoidconjugatevaccine #Gskvaccineinstitute

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

10 PCOS Warning Signs That Need Your AttentionDecember 27, 2024
Experts Dub 2024 as the Year of Technologies and Innovations in Healthcare; Stress on further Integration of Technologies December 27, 2024
Aakash Healthcare Partners with Japan for Groundbreaking Surgical Intervention: A Global Collaboration to Revolutionize Cardiovascular CareDecember 26, 2024
Traditional Medicine Goes Global: How Ayush 2024 Reimagined WellnessDecember 26, 2024
Aster Guardians Global Nursing Award 2025 worth INR 2 Crore now open for nominations worldwide December 26, 2024
Holiday Season Round the Corner? 6 Daily Habits That Could Be The Reason Behind Your Fatty LiverDecember 26, 2024
Healing the Nation: Doctors as Architects of a Healthier FutureDecember 26, 2024
Brewing Health Benefits: Can Coffee and Tea Help Fight Head and Neck Cancers?December 26, 2024
Seven-Year-Old Fights Back Against Rare Autoimmune DiseaseDecember 26, 2024
Olympus Named to Dow Jones Sustainability World Index for the Fourth Consecutive YearDecember 26, 2024
American Oncology Institute (AOI) in Nagpur Restores Mobility with KyphoplastyDecember 26, 2024
Sanjeevani Healthcare & Wellness Expo 2024: A Dynamic Platform for Global Healthcare CollaborationDecember 23, 2024
Ranitidine: Saviour or Suspect? The Truth Behind the Stomach Acid RemedyDecember 23, 2024
From One-Size-Fits-All to Precision Medicine: The New Hope for Rare Bone Cancer PatientsDecember 23, 2024
World Meditation Day: India’s Gift of Peace to a Chaotic WorldDecember 23, 2024
Breaking New Ground in Migraine Care: A Landmark Session on Diagnosis and TreatmentDecember 23, 2024
Black Angels remind us of centuries of injustices plaguing the TB responseDecember 20, 2024
Healthcare Startups to Watch Out for in 2025December 20, 2024
Biobank Blueprint: Redefining Diabetes Diagnosis and Treatment in IndiaDecember 20, 2024
The Future of Malaria Prevention: Can This Vaccine Eliminate the Disease?December 20, 2024